Ignite Creation Date:
2025-12-24 @ 12:17 PM
Ignite Modification Date:
2026-02-25 @ 12:53 AM
Study NCT ID:
NCT03927261
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-08
First Post:
2019-04-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Sponsor:
Precigen, Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
PRGN3006-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None